<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05798780</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-22330</org_study_id>
    <nct_id>NCT05798780</nct_id>
  </id_info>
  <brief_title>The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors</brief_title>
  <official_title>The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to design a physical activity and dietary intervention for head&#xD;
      and neck cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2023</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Recruited - Feasibility</measure>
    <time_frame>12 Months</time_frame>
    <description>The study will be deemed feasible if ≥ 60% of eligible participants are enrolled</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Complete Questionnaire - Retention - Feasibility</measure>
    <time_frame>12 weeks</time_frame>
    <description>The study will be deemed feasible if ≥ 70% of participants complete post intervention questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Satisfaction of Timeline - Feasibility</measure>
    <time_frame>12 weeks</time_frame>
    <description>The study will be deemed feasible if ≥ 70% of participants like the timing of the intervention using a likert scale (scale range Strongly agree to Strongly disagree)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Average Attendance - Assessment Completion - Adherence</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participant assessment completion will be deemed successful if participant average attendance is ≥10 weeks of sessions (out of 12)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Complete Task/Goals - Adherence</measure>
    <time_frame>12 weeks</time_frame>
    <description>Study adherence will be deemed successful if ≥70% of participants report weekly tasks/goals adherence (e.g., gym and diet)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Satisfaction Assessed with 5 Point Scale - Acceptability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants satisfaction will be measured using a 5 point scale (1 is the lowest, 5 is the highest) exit survey administered at the post-intervention follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Intent to Continue Assessed with 5 Point Scale - Acceptability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants intent to continue will be measured using a 5 point scale (1 is the lowest, 5 is the highest) exit survey administered at the post-intervention follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Knowledge Gained Assessed with 5 Point Scale - Acceptability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participants knowledge gained will be measured using a 5 point scale (1 is the lowest, 5 is the highest) exit survey administered at the post-intervention follow-up.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Oral Cavity Cancer</condition>
  <condition>Oropharynx Cancer</condition>
  <condition>Hypopharynx Cancer</condition>
  <condition>Larynx Cancer</condition>
  <arm_group>
    <arm_group_label>ENHANCE Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will participate in 2 in-person supervised resistance training sessions every week for the 7 weeks (during radiation), followed by 2 ZOOM video conference supervised resistance training sessions every week for 5 weeks (after radiation). During radiation, participants will be provided 15 meals each week for 7 weeks. Participants will also attend weekly dietary coaching sessions. Participants will receive a Fitbit to wear continuously 24/7 over 12-weeks to track steps and activity intensity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care + Fitbit</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive handouts with diet and exercise education. Participants will receive a Fitbit to wear continuously 24/7 over 12-weeks to track steps and activity intensity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ENHANCE Intervention</intervention_name>
    <description>During radiation, participants will attend in-person supervised resistance training sessions once a week for 7 weeks, followed by 2 ZOOM video conference supervised resistance training sessions every week for 5 weeks, after radiation. Sessions will last approximately 30 minutes. During radiation, participants will be provided 15 meals each week for 7 weeks, 105 meals total. Participants will be asked to participate in 1 weekly dietary coaching session (in-person during radiation and video conference following radiation), create weekly SMART goals, follow an alternative Mediterranean diet pattern, and log all meals, snacks, and supplements consumed for the 12-week intervention.</description>
    <arm_group_label>ENHANCE Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  Newly diagnosed tumors of the oral cavity, oropharynx, hypopharynx, or larynx&#xD;
&#xD;
          -  No documented or observable psychiatric or neurological disorders that would interfere&#xD;
             with study participation (e.g., dementia, psychosis)&#xD;
&#xD;
          -  Able to speak and read English&#xD;
&#xD;
          -  Able to consume food orally&#xD;
&#xD;
          -  Willing to consume an alternative Mediterranean diet&#xD;
&#xD;
          -  Scheduled to receive treatment with radiation or chemoradiation&#xD;
&#xD;
          -  Screened via the Physical Activity Readiness Questionnaire (PAR-Q+) with medical&#xD;
             clearance of treating physicians, as necessary&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant&#xD;
&#xD;
          -  Head and Neck Cancer not the primary diagnosis&#xD;
&#xD;
          -  Patients scheduled to receive surgery&#xD;
&#xD;
          -  Patients on enteral or parental nutrition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvia Crowder, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvia Crowder, PhD</last_name>
    <phone>813-745-6849</phone>
    <email>Sylvia.Crowder@moffitt.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Bryant</last_name>
      <phone>813-745-2168</phone>
      <email>Crystal.Bryant@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Sylvia Crowder, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathan Parker, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Jim, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Caudell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kedar Kirtane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bob Gore, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinicaltrialssearch?DiseaseSite=&amp;q=22330</url>
    <description>Moffitt Cancer Center Clinical Trial Search</description>
  </link>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>April 4, 2023</last_update_submitted>
  <last_update_submitted_qc>April 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

